Mitochondria are the main site for energy conversion in the cell. Under certain circumstances, such as excess calcium retention or production of reactive oxygen species, a pore forms at contact sites between the outer and the normally impermeable inner mitochondrial membrane. The ensuing osmotic mitochondrial swelling and loss of bioenergetic function is referred to as the mitochondrial permeability transition (mPT). Certain drugs of the cyclosporine family, such as cyclosporin A (CsA), are reversible inhibitors of mPT via direct interaction with cyclophilin D, which is a known part of the pore forming complex. The limited blood-brain barrier penetration by these drugs has instigated a search for mPT modulating effects among already clinically available compounds with better access to the central nervous system.
In the present study we show that the choice of methods used to evaluate swelling in vitro of mitochondria derived from the CNS could lead to an underestimation of the ability of brain mitochondria to undergo mPT.
We have also re-evaluated minocycline, a semisynthetic antibiotic, which has been reported as a direct mPT inhibitor and found that the previously stated mitochondrial effects (depolarization of the mitochondrial membrane potential and inhibition of calcium-induced swelling) are likely secondary or related to mitochondrial toxicity.
In a successive evaluation of 12 putative mPT inhibiting compounds, none displayed effects comparable to cyclophilin D inhibition by the non-immunosuppressive cyclophilin inhibitor D-MeAla3-EtVal4-Cyclosporin (Debio 025). Mitochondrial effects were often related to a compromised mitochondrial respiratory capacity. Drugs that uncouple or inhibit mitochondrial respiration will decrease mitochondrial calcium uptake but simultaneously reduce calcium retention capacity (CRC) and thus sensitize mitochondria towards mPT. In addition, a compromised respiratory function will impede ATP generation of mitochondria.
It is concluded that screening for putative inhibitors of mPT in complex disease models (such as cellular systems or in vivo models) is extremely prone to confounding influence, the most important being uncoupling and respiratory inhibition. It is suggested that the minimal requirement for a direct mPT inhibitor should include evidence for a specific mitochondrial target and an increased mitochondrial CRC at concentrations that can be translated to safe clinical use.
|Tilldelningsdatum||2010 apr. 24|
|Status||Published - 2010|
Place: Belfragesalen, Biomedicinskt Centrum, Lund
Name: Andersen, Peter M.
Affiliation: Institutionen för farmakologi och klinisk neurovetenskap, Umeå Universitet
The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Laboratory for Experimental Brain Research (013041000), Neurology, Malmö (013027010)